Publication:
<sup>131</sup>I-rituximab treatment in patient with relapsed non-Hodgkin's lymphoma: The first case report in Thailand

Simple item page
dc.contributor.authorArpakorn Kositwattanarerken_US
dc.contributor.authorWirote Changmuangen_US
dc.contributor.authorJatupol Sangsuriyanen_US
dc.contributor.authorKittiphong Thongklamen_US
dc.contributor.authorChanika Sritaraen_US
dc.contributor.authorChirawat Utamakulen_US
dc.contributor.authorWichana Chamroonraten_US
dc.contributor.authorKanungnij Thamniraten_US
dc.contributor.authorYoch Anongpornyochkulen_US
dc.contributor.authorSuporn Chancharuneeen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherThailand Institute of Nuclear Technology (Public Organization)en_US
dc.date.accessioned2018-10-19T05:22:46Z
dc.date.available2018-10-19T05:22:46Z
dc.date.issued2013-06-13en_US
dc.description.abstractRadioimmunotherapy (RIT) with131I-rituximab is a safe and effective treatment in patients with relapsed, refractory follicular lymphoma. The authors demonstrated the first case of131I-rituximab treatment in the patient with relapsed non-Hodgkin's lymphoma (NHL) in Thailand. There was no immediate complication after treatment. Impressive treatment response occurred.en_US
dc.identifier.citationJournal of the Medical Association of Thailand. Vol.96, No.6 (2013), 756-760en_US
dc.identifier.issn01252208en_US
dc.identifier.other2-s2.0-84878748312en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/32298
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84878748312&origin=inwarden_US
dc.subjectMedicineen_US
dc.title<sup>131</sup>I-rituximab treatment in patient with relapsed non-Hodgkin's lymphoma: The first case report in Thailanden_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84878748312&origin=inwarden_US

Files

Collections

Scopus 2011-2015